Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Raw Materials (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Raw Materials for 12 consecutive years, with $24.6 million as the latest value for Q3 2022.

  • On a quarterly basis, Raw Materials fell 9.4% to $24.6 million in Q3 2022 year-over-year; TTM through Jul 2022 was $24.6 million, a 9.4% decrease, with the full-year FY2022 number at $30.3 million, up 6.89% from a year prior.
  • Raw Materials was $24.6 million for Q3 2022 at Usana Health Sciences, down from $30.6 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $30.9 million in Q4 2021 to a low of $14.1 million in Q1 2020.
  • A 5-year average of $23.6 million and a median of $22.5 million in 2019 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: tumbled 37.08% in 2020, then surged 93.29% in 2021.
  • Usana Health Sciences' Raw Materials stood at $19.5 million in 2018, then dropped by 18.58% to $15.9 million in 2019, then soared by 42.13% to $22.6 million in 2020, then skyrocketed by 37.05% to $30.9 million in 2021, then dropped by 20.37% to $24.6 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Raw Materials are $24.6 million (Q3 2022), $30.6 million (Q2 2022), and $30.3 million (Q1 2022).